User profiles for "author:Sijin Wen"
Sijin WenWest Virginia University Verified email at hsc.wvu.edu Cited by 16233 |
[HTML][HTML] COVID-19 vaccination and neurological manifestations: a review of case reports and case series
S Sriwastava, K Sharma, SH Khalid, S Bhansali… - Brain sciences, 2022 - mdpi.com
Background: With 10 vaccines approved by the WHO and nearly 48% of people fully
vaccinated worldwide, we have observed several individual case studies of neurological …
vaccinated worldwide, we have observed several individual case studies of neurological …
[HTML][HTML] COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from …
S Sriwastava, M Tandon, S Podury, A Prasad… - Journal of …, 2021 - Springer
Background The literature on neurological manifestations in COVID-19 patients has been
rapidly increasing with the pandemic. However, data on CNS inflammatory disorders in …
rapidly increasing with the pandemic. However, data on CNS inflammatory disorders in …
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
CS Tam, S O'Brien, W Wierda… - Blood, The Journal …, 2008 - ashpublications.org
Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224
patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia …
patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia …
[HTML][HTML] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda, S O'Brien, S Wen, S Faderl… - Journal of clinical …, 2005 - nlp.case.edu
Purpose The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination
of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated …
of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated …
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
Tumor-infiltrating cytotoxic T lymphocytes (TILs), including CD8 TILs, have been associated
with favorable clinical outcomes in multiple tumor types. Tumor-infiltrating CD8 T cells and …
with favorable clinical outcomes in multiple tumor types. Tumor-infiltrating CD8 T cells and …
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler… - Clinical cancer …, 2012 - AACR
Purpose: We initiated a personalized medicine program in the context of early clinical trials,
using targeted agents matched with tumor molecular aberrations. Herein, we report our …
using targeted agents matched with tumor molecular aberrations. Herein, we report our …
Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating …
A Chi, H Chen, S Wen, H Yan, Z Liao - Radiotherapy and Oncology, 2017 - Elsevier
Purpose To assess hypo-fractionated particle beam therapy (PBT)'s efficacy relative to that
of photon stereotactic body radiotherapy (SBRT) for early stage (ES) non-small cell lung …
of photon stereotactic body radiotherapy (SBRT) for early stage (ES) non-small cell lung …
[HTML][HTML] Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated …
Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
A Ferrajoli, BN Lee, EJ Schlette… - Blood, The Journal …, 2008 - ashpublications.org
This study investigated the activity of lenalidomide in patients with relapsed/refractory
chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose …
chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose …
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
AM Aparicio, AL Harzstark, PG Corn, S Wen… - Clinical cancer …, 2013 - AACR
Purpose: Clinical features characteristic of small-cell prostate carcinoma
(SCPC),“anaplastic,” often emerge during the progression of prostate cancer. We sought to …
(SCPC),“anaplastic,” often emerge during the progression of prostate cancer. We sought to …